Last reviewed · How we verify

Tolmar Inc. — Portfolio Competitive Intelligence Brief

Tolmar Inc. pipeline: 2 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 2 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Taclonex Taclonex marketed Other
Anastrozole Tablets Anastrozole Tablets marketed Aromatase inhibitor Aromatase (CYP19A1) Oncology
Exemestane Tablets Exemestane Tablets phase 3 Aromatase inhibitor (steroidal) Aromatase (CYP19A1) Oncology
TOL2506 TOL2506 phase 3 GnRH agonist GnRH receptor Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 2 shared drug classes
  2. Abbott · 1 shared drug class
  3. Biogen · 1 shared drug class
  4. AstraZeneca · 1 shared drug class
  5. Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
  6. Bayer · 1 shared drug class
  7. Amgen · 1 shared drug class
  8. AbbVie (prior sponsor, Abbott) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Tolmar Inc.:

Cite this brief

Drug Landscape (2026). Tolmar Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tolmar-inc. Accessed 2026-06-10.

Related